tetano
Editor, Senior Moderator
BMJ Case Rep
. 2025 Mar 5;18(3):e263299.
doi: 10.1136/bcr-2024-263299. Acquired haemophilia A following COVID-19 vaccine
Jennifer Kate Beckerman[SUP] 1 [/SUP], Omar Yaghi[SUP] 2 [/SUP], Samah Nassereddine[SUP] 3 [/SUP]
Affiliations
Acquired haemophilia A (AHA) is caused by autoantibodies that neutralise Factor VIII (FVIII) and can cause severe bleeding. The COVID-19 vaccine may trigger the development of acquired autoantibodies against coagulation factors, which is associated with high morbidity. This is a case of a man who needed medical attention and presented with haematochezia and haematoma formation following a colonoscopy and root canal procedure. Both events were preceded by a COVID-19 mRNA booster vaccination. Laboratory data was significant for a prolonged activated partial thromboplastin time (aPTT) of 55 s which prompted a haematology consult. A further work-up revealed the presence of an acquired FVIII inhibitor correlating with a severely reduced activity level. Treatment was given to eradicate the inhibitor with steroids and cyclophosphamide, while a thorough investigation was initiated for possible causes. Prompt recognition of an acquired inhibitor is essential for timely management to control bleeding.
Keywords: COVID-19; Haematology (incl blood transfusion); Immunological products and vaccines; Medical management.
. 2025 Mar 5;18(3):e263299.
doi: 10.1136/bcr-2024-263299. Acquired haemophilia A following COVID-19 vaccine
Jennifer Kate Beckerman[SUP] 1 [/SUP], Omar Yaghi[SUP] 2 [/SUP], Samah Nassereddine[SUP] 3 [/SUP]
Affiliations
- PMID: 40044482
- DOI: 10.1136/bcr-2024-263299
Acquired haemophilia A (AHA) is caused by autoantibodies that neutralise Factor VIII (FVIII) and can cause severe bleeding. The COVID-19 vaccine may trigger the development of acquired autoantibodies against coagulation factors, which is associated with high morbidity. This is a case of a man who needed medical attention and presented with haematochezia and haematoma formation following a colonoscopy and root canal procedure. Both events were preceded by a COVID-19 mRNA booster vaccination. Laboratory data was significant for a prolonged activated partial thromboplastin time (aPTT) of 55 s which prompted a haematology consult. A further work-up revealed the presence of an acquired FVIII inhibitor correlating with a severely reduced activity level. Treatment was given to eradicate the inhibitor with steroids and cyclophosphamide, while a thorough investigation was initiated for possible causes. Prompt recognition of an acquired inhibitor is essential for timely management to control bleeding.
Keywords: COVID-19; Haematology (incl blood transfusion); Immunological products and vaccines; Medical management.